Hi Reggie, I fail to see how a successful phase 3 will bring us to $4-5. The baseline we were at was over $3.50 when we were waiting for a big pharma partner. A successful phase 3 will open doors and leave us in a position that is not even comparable to when we were at $3.50. Investors are clearly aware of this stock.
Surely if trof passes we get further interest from other pharma companies, we lock in ACADIA into a deal they can not refuse, we have more medicines that are up and coming, still hold ROW rights...my guess is at the absolute bare minimum we will be sitting at $5.50 - $6. Even then that is low.
If we are at $4 after the success of P3 then the market is not working as intended and is basing value on anything but fundamentals.
Ann: Phase 3 enrolment successfully completed, results in Q4 2021, page-89
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.17 |
Change
0.070(0.35%) |
Mkt cap ! $2.578B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.53 | $20.14 | $4.102M | 202.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 249 | $20.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.31 | 790 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |